Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies

被引：89

作者：

Chen, Ding ^{[1
]}

Gallagher, Sandra ^{[2
]}

Monson, Nancy L. ^{[1
]}

Herbst, Ronald ^{[3
]}

Wang, Yue ^{[3
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA

[2] MedImmune, Dept Project Management, Gaithersburg, MD 20878 USA

[3] MedImmune, Dept Oncol Res, Gaithersburg, MD 20878 USA

来源：

JOURNAL OF CLINICAL MEDICINE | 2016年 / 5卷 / 12期

关键词：

CD19; B-cell depletion; autoimmunity; multiple sclerosis; neuromyelitis optica; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; LIVED PLASMA-CELLS; MULTIPLE-SCLEROSIS; CD19; ACTIVATION; MEDI-551; SUBSET; MICE; AQUAPORIN-4; LYMPHOCYTES;

D O I：

10.3390/jcm5120107

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for improved efficacy. CD19 has emerged as a promising target for the depletion of B cells as well as CD19-positive plasmablasts and plasma cells. Inebilizumab (MEDI-551), an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells, is currently being evaluated in MS and neuromyelitis optica. This review discusses the role of B cells in autoimmune neurological disorders, summarizes the development of inebilizumab, and analyzes the recent results for inebilizumab treatment in an autoimmune encephalitis mouse model. The novel insights obtained from these preclinical studies can potentially guide future investigation of inebilizumab in patients.

引用

页数：12

共 74 条

[11] Biological Perspectives Anti-NMDA Receptor Encephalitis [J].

Dowben, Jonathan S. ;

Kowalski, Peter C. ;

Keltner, Norman L. .

PERSPECTIVES IN PSYCHIATRIC CARE, 2015, 51 (04) :236-240

[12] B cells and antibodies in progressive multiple sclerosis: Contribution to neurodegeneration and progression [J].

Fraussen, Judith ;

de Bock, Laura ;

Somers, Veerle .

AUTOIMMUNITY REVIEWS, 2016, 15 (09) :896-899

[13] Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice [J].

Gallagher, Sandra ;

Turman, Sean ;

Yusuf, Isharat ;

Akhgar, Ahmad ;

Wu, Yuling ;

Roskos, Lorin K. ;

Herbst, Ronald ;

Wang, Yue .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 36 :205-212

[14] MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19 [J].

Gallagher, Sandra ;

Yusuf, Isharat ;

McCaughtry, Tom M. ;

Turman, Sean ;

Sun, Hong ;

Kolbeck, Roland ;

Herbst, Ronald ;

Wang, Yue .

ARTHRITIS & RHEUMATOLOGY, 2016, 68 (04) :965-976

[15] Myasthenia gravis - autoantibody characteristics and their implications for therapy [J].

Gilhus, Nils Erik ;

Skeie, Geir Olve ;

Romi, Fredrik ;

Lazaridis, Konstantinos ;

Zisimopoulou, Paraskevi ;

Tzartos, Socrates .

NATURE REVIEWS NEUROLOGY, 2016, 12 (05) :259-U91

[16] Characterization of B cells in muscle-specific kinase antibody myasthenia gravis [J].

Guptill, Jeffrey T. ;

Yi, John S. ;

Sanders, Donald B. ;

Guidon, Amanda C. ;

Juel, Vern C. ;

Massey, Janice M. ;

Howard, James F., Jr. ;

Scuderi, Flavia ;

Bartoccioni, Emanuela ;

Evoli, Amelia ;

Weinhold, Kent J. .

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2015, 2 (02) :e77

[17] Long-Lived Plasma Cells Are Contained within the CD19-CD38hiCD138+ Subset in Human Bone Marrow [J].

Halliley, Jessica L. ;

Tipton, Christopher M. ;

Liesveld, Jane ;

Rosenberg, Alexander F. ;

Darce, Jaime ;

Gregoretti, Ivan V. ;

Popova, Lana ;

Kaminiski, Denise ;

Fucile, Christopher F. ;

Albizua, Igor ;

Kyu, Shuya ;

Chiang, Kuang-Yueh ;

Bradley, Kyle T. ;

Burack, Richard ;

Slifka, Mark ;

Hammarlund, Erika ;

Wu, Hao ;

Zhao, Liping ;

Walsh, Edward E. ;

Falsey, Ann R. ;

Randall, Troy D. ;

Cheung, Wan Cheung ;

Sanz, Inaki ;

Lee, F. Eun-Hyung .

IMMUNITY, 2015, 43 (01) :132-145

[18] CD19 as an attractive target for antibody-based therapy [J].

Hammer, Ohad .

MABS, 2012, 4 (05) :571-577

[19] B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody [J].

Herbst, Ronald ;

Wang, Yue ;

Gallagher, Sandra ;

Mittereder, Nanette ;

Kuta, Ellen ;

Damschroder, Melissa ;

Woods, Rob ;

Rowe, Daniel C. ;

Cheng, Li ;

Cook, Kim ;

Evans, Krista ;

Sims, Gary P. ;

Pfarr, David S. ;

Bowen, Michael A. ;

Dall'Aqua, William ;

Shlomchik, Mark ;

Tedder, Thomas F. ;

Kiener, Peter ;

Jallal, Bahija ;

Wu, Herren ;

Coyle, Anthony J. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (01) :213-222

[20] Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes [J].

Hinson, Shannon R. ;

Romero, Michael F. ;

Popescu, Bogdan F. Gh. ;

Lucchinetti, Claudia F. ;

Fryer, James P. ;

Wolburg, Hartwig ;

Fallier-Becker, Petra ;

Noell, Susan ;

Lennon, Vanda A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (04) :1245-1250

← 1 2 3 4 5 6 7 8 →